This is the authors' abstract. We don't add key points for this paper.
The Hippo pathway effector Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) play a critical role in promoting lung cancer progression, but paradoxically increase tumor cell sensitivity to ferroptosis, a form of lipid peroxidation-driven cell death. The mechanism through which YAP/TAZ-high cells evade ferroptosis during cancer progression remains unclear. Here, we showed that YAP/TAZ-low lung cancer cells confer durable ferroptosis resistance to neighboring YAP/TAZ-high cells through a non-cell-autonomous mechanism. Using murine lung carcinoma cell coculture models, we demonstrated that transient exposure to YAP/TAZ-deficient cells induces a stable, contact-independent ferroptosis-resistant state in wild-type (WT) cells, enhancing their metastatic seeding capacity in vivo. This adaptation is mediated by the upregulation of Gch1, which encodes GTP cyclohydrolase 1 and suppresses ferroptosis via the synthesis of the antioxidant metabolite tetrahydrobiopterin (BH4). GCH1 overexpression alone was sufficient to confer ferroptosis resistance in WT cells, whereas conditioned medium from YAP/TAZ-deficient cells replicated this effect, indicating that a soluble factor is involved in Gch1 induction. Importantly, the genetic deletion of Gch1 in YAP/TAZ-deficient cells abolished their ability to protect WT cells, confirming its essential role in this intercellular program. Our findings revealed a Hippo pathway-linked ferroptosis resistance mechanism and suggested that intra-tumoral heterogeneity in YAP/TAZ activity promotes metastatic fitness by enabling the survival of ferroptosis-prone cells via antioxidant signaling.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Saleh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: